FDA GUIDANCENovember 06, 2026
FDA Grants Premarket Approval (PMA P130021): Evolut FX Delivery Catheter System of the Evolut FX Transcatheter Aortic Valve System; Evolut FX+ Transcatheter Aorti by Medtronic, Inc.
Affected Product:Evolut FX Delivery Catheter System of the Evolut FX Transcatheter Aortic Valve System; Evolut FX+ Transcatheter Aorti
Recalling Firm / Manufacturer:Medtronic, Inc.
Reference / Recall Number:P130021
Executive Summary:
FDA awards Class III Premarket Approval (PMA P130021) for Evolut FX Delivery Catheter System of the Evolut FX Transcatheter Aortic Valve System; Evolut FX+ Transcatheter Aorti sponsored by Medtronic, Inc..
The FDA Center for Devices and Radiological Health has granted Premarket Approval (PMA) for Evolut FX Delivery Catheter System of the Evolut FX Transcatheter Aortic Valve System; Evolut FX+ Transcatheter Aorti, classified as a Class III life-supporting or life-sustaining medical device.
PMA Approval Dossier
- PMA Number: P130021
- Applicant: Medtronic, Inc.
- Device Designation: Evolut FX Delivery Catheter System of the Evolut FX Transcatheter Aortic Valve System; Evolut FX+ Transcatheter Aorti
- Product Code: NPT
- Decision Code: OK30
Approval was based on rigorous review of valid scientific evidence, including bench testing, animal studies, and human clinical trial outcomes establishing a reasonable assurance of safety and effectiveness.
Official Regulatory Docket:Open Agency Docket